Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that changes in immune cell infiltration and immune-related gene expression may contribute to the immune microenvironment changes in male androgenetic alopecia.

This report discusses a case of extensive keloid formation at the donor site following hair transplantation, emphasizing the need for surgeons to be cautious in patients with a history of keloid tendencies.

This review discusses the complexities of hidradenitis suppurativa pathogenesis, highlighting issues with Notch signaling, immune dysregulation, and the role of keratinocytes and ECM, but reports no new clinical results.

This article reviews various drugs reported to cause alopecia, including cytostatics and anticoagulants, but does not present new research results; it suggests that drug-related hair loss can be difficult to prove.

Some drugs can cause hair loss or growth, but hair usually returns to normal after stopping the drug.

Many medications can cause hair loss or excessive hair growth, which is usually reversible after stopping the drug.

This study demonstrated that RNA interference targeting mutant keratin genes can effectively correct hair shaft structural defects in a mouse model by reducing mutant gene expression.

This review discusses genetic and pharmacogenetic insights, along with RNA interference technologies, for developing personalized therapies for androgenetic alopecia, yet presents no new clinical results.

This study found that intradermal injection of a specially designed RNA molecule, cp-asiAR, successfully reduced androgen receptor levels and promoted hair growth in a mouse model of androgenetic alopecia, while also improving hair follicle characteristics in ex vivo human scalp tissues without significant toxicity.

This study found that immune privilege collapse in the hair follicle bulge and associated immune responses may contribute significantly to the pathogenesis of lichen planopilaris, suggesting a potential autoimmune basis for the disease.

In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.

This study found that human placenta hydrolysate effectively inhibited atopic dermatitis development in stimulated human cells and a mouse model, suggesting its potential as a therapeutic agent for related skin diseases.

The study suggests that immune privilege collapse in bulge cells and the involvement of pro-inflammatory cytokine interferon-γ contribute to hair follicle stem cell loss in lichen planopilaris.

In this animal study, researchers discovered that CD4 T cells from mice with alopecia areata can induce the disease more efficiently than those from unaffected mice, likely by supporting CD8 T cell activation and hair follicle attack.

This study used spatial transcriptomics to investigate T cell-hair follicle interactions in cutaneous lupus erythematosus across mice, dogs, and humans, finding that CXCR3+ T cells and B cells are enriched in lesional skin, with implications for potential therapeutic targets.

This study found that JAK1 and JAK2 inhibitors increase β-catenin activity in human hair follicle cells, suggesting an additional therapeutic mechanism for treating severe alopecia areata.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.

This article reviews current treatments for alopecia areata, discussing the potential role of JAK inhibitors and noting the need for further clinical trials, but it reports no new results.

This study found that Crataegi Fructus water extract may promote hair growth in mice by enhancing hair density, thickness, and length and activating the Wnt/β-catenin signaling pathway.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

This study found that impairments in cholesterol biosynthesis in hair follicles of primary cicatricial alopecia patients trigger an inflammatory immune response, potentially linking sterols to inflammation in the disease's pathogenesis.

Combination therapies might work better for some vitiligo patients, but results vary.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This report diagnosed a 68-year-old man with comedonal folliculotropic mycosis fungoides based on clinical and histopathological findings, and found pegylated interferon alpha-2a with isotretinoin beneficial in reducing skin lesions.

This review discusses sex-based differences in immune responses, focusing on genetic, hormonal, and microbiome factors influencing infections like COVID-19, and reports no clinical results.

This study found that several anti-cancer agents strongly inhibit DNA synthesis in human hair germinative cells, while certain cytokines showed only slight inhibition.

This paper discusses the challenges of diagnosing drug eruptions, emphasizing the nonspecific patterns and unclear pathomechanisms, and calls for further research using new biologic drugs to understand these reactions better.

This review discusses the diverse range of skin manifestations in children with COVID-19 and highlights the complexity of clinical assessment due to varied presentations; it reports no new clinical findings.

In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.

This article from the 4th Intercontinental Meeting of Hair Research Societies provides no abstract or new findings.